

29th July 2021

Ajanta House,
Charkop, Kandivli (West),
Mumbai 400 067
India

T +91 22 6606 1000
F +91 22 6606 1200
E info@ajantapharma.com
W www.ajantapharma.com

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
--	--

Re: Outcome of the Board Meeting

Dear Sir/Madam,

At the Board meeting held today, the Board has *inter-alia* approved and taken on record Unaudited Financial results for the quarter ended 30th June 2021. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:

- i. Press Release being issued on the Results for the quarter ended 30th June 2021;
- ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2021;
- iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2021;
- iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2021;
- v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2021;
- vi. Investors' presentation.

Kindly note that the meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 3.40 p.m. and take the above on your records.

Thanking You,

Yours faithfully,

GAURANG SHAH
VP – Legal & Company Secretary

Encl.: a/a

PAT up by 18% (1st Quarter FY 2022 Consolidated Results)

Mumbai, 29th July, 2021: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 1st quarter ended 30th June 2021.

Q1 FY 2022 performance highlights (compared to Q1 FY 2021)

- Revenue from Operations at Rs. 748 cr. against Rs. 668 cr.; up by 12%.
- EBITDA at Rs. 220 cr. against Rs. 223 cr.; EBITDA at 29% of Revenue from Operations.
- Profit after tax at Rs. 174 cr. against Rs. 148 cr., PAT at 23% of Revenue from Operations.

India

Q1 FY 2022, India sales was Rs. 229 cr. (against Rs. 174 cr.), up 32%.

As per IQVIA MAT June 2021, we have posted healthy growth of 14% in Cardiology (segment growth of 15%), 17% in Ophthalmology (segment growth of 10%), 21% in Dermatology (segment growth of 12%) and 30% in Pain Management (segment growth of 10%).

Exports

Q1 FY 2022, total export sales were Rs. 513 cr. (against Rs. 483 cr.) posting growth of 6%. Segment wise break-up is given below:

Emerging market branded generic	<p>Sale was Rs. 291 cr. against (Rs. 271 cr.) posting 7% growth. Out of which:</p> <ul style="list-style-type: none"> • Africa branded generic sale was Rs. 123 cr. (against Rs. 108 cr.) posting 15% growth. • Asia branded generic sale was Rs. 165 cr. (against Rs. 161 cr.) posting 3% growth.
US Generic	<p>Sale was Rs. 168 cr. (against Rs. 149 cr.) posting 13% growth.</p> <p>In US, during Q1 FY 2022, company received 1 ANDA final approval from US FDA. Out of 41 final ANDA approvals, we have commercialized 38 products. We hold 2 tentative approval and 15 ANDAs are awaiting US FDA approval. Company plans to file 10 to 12 ANDAs during this financial year.</p>
Africa Institution	<p>Sale was Rs. 54 cr. (against Rs. 62 cr.) posting (13%) de-growth.</p>

R&D

During Q1 FY 2022, R&D expenses were Rs. 45 cr., which is 6% of Revenue from Operations (For Q1 FY 2021 Rs. 31 cr.; 5% of Revenue from Operations)

Earnings Conference Call

The Company will host an Earnings conference call at 1730 hrs. IST (2000 hrs. SST/HKT, 1300 hrs. BST, 0800 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

Date and Time	July 29, 2021 at 1730 – 1830 hrs IST 2000 – 2100 hrs SST/HKT 1300 – 1400 hrs BST 0800 – 0900 hrs US ET
Dial-in Numbers	
Universal Access	Primary Access: (+91 22 6280 1542) (+91 22 7115 8372)
Diamond pass link	Click here to register
International Toll	USA: +1 3233868721 UK: +44 2034785524 Hong Kong: +852 30186877 Singapore: +65 31575746
International Toll Free	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centre is located in Mumbai. Company has 8 world class manufacturing facilities located in India and Mauritius.

For last 10 financial years, company has posted healthy performance with its Revenue from Operations growing at 17% CAGR and net profit at 27% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement

Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2021

₹ in Crore

Particulars	3 months ended			Year Ended
	30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
	Unaudited	Audited (Refer Note 3)	Unaudited	Audited
Income				
Revenue from operations	747.99	756.84	668.20	2,889.69
Other income	32.63	2.53	13.12	25.98
Total Income	780.62	759.37	681.32	2,915.67
Expenses				
Cost of materials consumed	187.23	171.85	153.87	706.41
Purchases of stock-in-trade	36.51	20.38	17.65	89.54
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(52.08)	(24.32)	(18.42)	(150.90)
Employee benefits expense	157.99	145.77	135.79	548.25
Finance costs	1.51	2.56	1.63	8.27
Depreciation and amortisation expense	30.88	30.60	28.02	116.09
Other expenses	198.13	183.75	156.09	697.83
Total Expenses	560.17	530.59	474.63	2,015.49
Profit before exceptional items and tax	220.45	228.78	206.69	900.18
Exceptional Item	-	-	-	-
Profit before tax	220.45	228.78	206.69	900.18
Tax Expense				
Current Tax (net)	44.72	83.32	53.13	261.36
Deferred Tax (net)	1.98	(13.80)	5.80	(15.05)
Profit after tax	173.75	159.26	147.76	653.87
Other Comprehensive Income (OCI)				
Items that will be reclassified subsequently to profit or loss	(2.00)	(2.82)	1.42	(5.12)
Income tax relating to Items that will be reclassified subsequently to profit or loss	-	-	-	-
Items that will not be reclassified subsequently to profit or loss	(0.51)	0.74	(0.98)	(2.04)
Income tax relating to items that will not be reclassified to profit or loss	0.18	(0.26)	0.34	0.71
Other Comprehensive Income for the year, net of tax	(2.33)	(2.34)	0.78	(6.45)
Total Comprehensive Income for the period	171.42	156.92	148.54	647.42
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.39	17.39	17.54	17.39
Other Equity				2,978.24
Earnings Per Share (Face value of ₹ 2 each)				
Basic - in ₹	20.08	18.40	16.93	75.09
Diluted - in ₹	20.08	18.40	16.93	75.09

Notes :

- The above consolidated financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 29 July 2021. The statutory auditors have expressed unmodified opinion. The review report has been filed with the stock exchange and is available on company website.
- The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- The figures for the quarter ended 31 March 2021 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2020.
- The Group continued to take into account the possible impacts of COVID-19 in preparation of the financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Group has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The Group will continue to closely monitor future economic conditions to ensure business continuity.
- The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- The Financial Results are available for investors at the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

SREEJA
RAJASEKH
ARAN
MARAR
Digitally signed
by SREEJA
RAJASEKHARAN
MARAR
Date: 2021.07.29
15:16:35 +05'30'
Mumbai, 29 July 2021

By order of the Board
For Ajanta Pharma Ltd.

YOGESH
MANNALAL
AGRAWAL
Digitally signed by
YOGESH
MANNALAL
AGRAWAL
Date: 2021.07.29
14:30:56 +05'30'

Yogesh M. Agrawal
Managing Director

B S R & Co. LLP

Chartered Accountants

14th Floor, Central Wing B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai – 400 063

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited quarterly consolidated financial results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015

To Board of Directors of Ajanta Pharma Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Ajanta Pharma Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), for the quarter ended 30 June 2021 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Ajanta Pharma (Mauritius) Limited (“APML”)	Wholly owned subsidiary
Ajanta Pharma USA Inc.	Wholly owned subsidiary
Ajanta Pharma Philippines Inc.	Wholly owned subsidiary
Ajanta Pharma Nigeria Limited	Wholly owned subsidiary
Ajanta Pharma (Mauritius) International Limited	Wholly owned subsidiary of APML

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Registered Office:

Limited Review Report on unaudited quarterly consolidated financial results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015 (Continued)

Ajanta Pharma Limited

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Statement includes the interim financial results of 2 subsidiaries which have not been reviewed, whose interim financial results reflect total assets of Rs. 118.77 crores as at 30 June 2021 and total revenue of Rs. 55.66 crores, total net profit after tax of Rs. 8.02 crores and total comprehensive income of Rs. 8.02 crores for the quarter ended 30 June 2021. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No. 101248W/W-100022

SREEJA
RAJASEKHARAN
MARAR

Digitally signed by SREEJA
RAJASEKHARAN MARAR
Date: 2021.07.29 14:55:46
+05'30'

Sreeja Marar
Partner

Mumbai
29 July 2021

Membership No. 111410
UDIN:21111410AAAABU7658

Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2021

₹ in Crore

Particulars	3 months ended			Year Ended
	30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
	Unaudited	Audited (Refer Note 3)	Unaudited	Audited
Income				
Revenue from operations	742.72	748.07	560.85	2,718.59
Other income	31.00	1.33	13.10	103.57
Total Income	773.72	749.40	573.95	2,822.16
Expenses				
Cost of materials consumed	184.43	171.53	153.32	704.09
Purchases of stock-in-trade	27.14	22.45	22.59	100.59
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(23.94)	7.78	(25.53)	(74.60)
Employee benefits expense	144.93	133.44	123.82	498.11
Finance costs	1.17	2.18	1.20	6.90
Depreciation and amortisation expense	29.76	29.48	26.86	111.49
Other expenses	177.14	165.79	113.22	573.49
Total Expenses	540.63	532.65	415.48	1,920.07
Profit before exceptional items and tax	233.09	216.75	158.47	902.09
Exceptional Item				
Exceptional Item	-	-	-	-
Profit before tax	233.09	216.75	158.47	902.09
Tax Expense				
Current Tax (net)	36.37	68.55	38.07	216.68
Deferred Tax (net)	3.26	(6.58)	4.71	9.77
Profit after tax	193.46	154.78	115.69	675.64
Other Comprehensive Income (OCI)				
Items that will not to be reclassified subsequently to profit or loss	(0.51)	0.74	(0.98)	(2.04)
Income tax relating to items that will not be reclassified to profit or loss	0.18	(0.26)	0.34	0.71
Other Comprehensive Income for the year, net of tax	(0.33)	0.48	(0.64)	(1.33)
Total Comprehensive Income for the period	193.13	155.26	115.05	674.31
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.39	17.39	17.54	17.39
Other Equity				2,867.59
Earnings Per Share (Face value of ₹ 2 each)				
Basic - in ₹	22.36	17.89	13.26	77.59
Diluted - in ₹	22.36	17.89	13.26	77.59

Notes :

1. The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 29 July 2021. The statutory auditors have expressed unmodified opinion. The review report has been filed with the stock exchange and is available on company website.

2. Other income includes :

	3 months ended			Year Ended
	30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
Dividend from subsidiaries (₹ in Crore)	-	-	-	83.21

3. The figures for the quarter ended 31 March 2021 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2020.

4. The Company continued to take into account the possible impacts of COVID-19 in preparation of the financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Company has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The Company will continue to closely monitor future economic conditions to ensure business continuity.

5. The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".

6. The Financial Results are available for investors at the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

SREEJA
RAJASEKH
ARAN
MARAR
Digitally signed
by SREEJA
RAJASEKHARAN
MARAR
Date: 2021.07.29
15:17:27 +05'30'

Mumbai, 29 July 2021

By order of the Board
For Ajanta Pharma Ltd.

YOGESH
MANNALAL
AGRAWAL
Digitally signed by
YOGESH MANNALAL
AGRAWAL
Date: 2021.07.29
14:31:34 +05'30'

Yogesh M. Agrawal
Managing Director

B S R & Co. LLP

Chartered Accountants

14th Floor, Central Wing B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai – 400 063

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited quarterly standalone financial results of Ajanta Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015

To the Board of Directors of Ajanta Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Ajanta Pharma Limited ('the Company') for the quarter ended 30 June 2021 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants

Firm's Registration No. 101248W/W-100022

SREEJA
RAJASEKHAR
AN MARAR

Digitally signed by
SREEJA RAJASEKHARAN
MARAR
Date: 2021.07.29
14:56:33 +05'30'

Sreeja Marar
Partner

Mumbai
29 July 2021

Membership No. 111410
UDIN: 21111410AAAABT5283

Registered Office:



INVESTOR PRESENTATION

Q1 FY 2022

(29th July 2021)



Safe Harbor Statement

This presentation may include certain 'forward looking statements', based on current expectations, forecasts and assumptions within the meaning of applicable laws and regulations. They are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

The Company disclaims any obligation to revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

This material is used during oral presentation; it is not a complete record of the discussion.

Content



India Business



Global Business



Infrastructure



Financial Highlights

01

India Business

India Branded Generic Business



15 Divisions
for 4 segments



2,800 MRs
Building efficiency



300+
Product Basket



1st to Market
Products

Continue to Focus on 4 Therapeutic Segments

Cardiology



Growth Continues

Ophthalmology



2nd largest in India

Dermatology








Growth Accelerates

Pain Management




Consistently
performing well

India - Segment Growth





IPM = Indian Pharmaceutical Market
Source: Iqvia, June MAT 2021

➤ Growth benchmarked with Industry



IPM = Indian Pharmaceutical Market
Source: Iqvia, June MAT 2021




> India - Ranking

	Mar 2005	June 2020	June 2021
Ophthalmology	28	2	2
Dermatology	98	15	15
Cardiology	38	17	18
Pain Management	NA	36	33
Ajanta Pharma	88	29	29

02

Global Business

Global Presence



Branded Generic – Emerging Markets

Broader Therapeutic Segments

Product Registrations

1,400+

Countries Across Asia & Africa

29

Customized Product Basket

200+



Anti-Malaria



Antibiotics



Gynecology



Vitamins



Cardiology



Gastro



Anti-Histamines



Respiratory



Neurology



Ophthalmology



Pain



Approvals
(1 in Q1 FY
2022)

43

Under
Approval

15







Filing Target
(1 filed in
Q1 FY 2022)

~ 10-12


Including 2 tentative approval

- 38 Products on shelf
- 2 products launched in Q1 FY 2022
- Growth little lower but expected to pick up in coming quarters.

Export Sales – Q1 (Consolidated)



> Total Consolidated Sales – Q1



Rs. cr.


	Q1 FY 2021	Q1 FY 2022	Gwth
India	174	229	32%
Exports	483	513	6%
Total Sales	657	741	13%

03

Infrastructure

Research & Development

R&D Spend (Excluding Capex)



Q1 FY 2021

Rs. 31 cr. (5%)

Q1 FY 2022

Rs. 45 cr. (6%)



Formulation Manufacturing

- 3 facilities at Aurangabad, Maharashtra
- 1 facility at Dahej, Gujarat
- 1 facility at Guwahati, Assam
- 1 facility at Pithampur, Madhya Pradesh
- 1 facility at Mauritius

API Manufacturing

- 1 facility at Waluj, Aurangabad, Maharashtra
(Captive Consumption)



Sterile Ophthalmic line



Tablet Compression Machine



Packing Machine

04

Financial Highlights

Detailed P&L – Q1 FY 2022 (Consolidated)


Rs. cr.	Q1 FY 2021	% to RO	Q1 FY 2022	% to RO
Revenue from Operations (RO)	668		748	
Other Income	13	2%	33	4%
Total Income	681		781	
Materials consumed	152	23%	171	23%
Employee Benefit	136	20%	158	21%
Finance Cost	2	0%	2	0%
Depreciation	28	4%	31	4%
Other Expenses	156	23%	198	26%
Total Expenses	474	70%	560	75%
Profit Before Tax	207	31%	221	29%
Tax Expense	59	9%	47	6%
Net Profit	148	22%	174	23%
Other Comprehensive Income	1	0%	(3)	0%
Total Comprehensive Income	149	22%	171	23%
EBITDA	223	33%	220	29%

> P&L Synopsis – Q1 FY 2022 (Consolidated)


Rs. cr.	Q1 FY 2021	%	Q1 FY 2022	%	% Growth
Exports	483	72%	513	68%	6%
Domestic	174	26%	229	31%	32%
Other Op. Income	11	2%	6	1%	(43%)
Revenue from Operations	668		748		12%
EBITDA	223	33%	220	29%	(1%)
PBT	207	31%	221	29%	7%
PAT	148	22%	174	23%	18%
Total Comprehensive Income	149	22%	171	23%	15%

5 Year Track Record (Consolidated)





Consolidated Total Income
(Rs. cr.)







PAT (Rs. cr.) & PAT Margin (%)






5 Year Track Record (Consolidated)



5 Year Track Record (Consolidated)



5 Year Track Record (Consolidated)



Q4 FY21 Earnings Conference Call

Earnings Conference Call Dial-in Information

Date and Time	July 29, 2021 at 1730 – 1830 hrs IST 2000 – 2100 hrs SST/HKT 1300 – 1400 hrs BST 0800 – 0900 hrs US ET
Dial-in Numbers	
Universal Access	Primary Access: +91 22 6280 1542 +91 22 7115 8372
Toll Number	USA: +1 3233868721 UK: +44 2034785524 Hong Kong: +852 30186877 Singapore: +65 31575746

Thank You

For more information please visit our website:

www.ajantapharma.com

For regular updates follow us on twitter

www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal - 022-66061377

rajeev.agarwal@ajantapharma.com

Abhineet Kumar – 022-66061814

abhineet.kumar@ajantapharma.com

Ajanta House, Charkop, Kandivli (W), Mumbai 400 067

CIN No. - L24230MH1979PLC022059